JP6685925B2 - 治療用として改善された特性を有するβ−ラクタマーゼ - Google Patents

治療用として改善された特性を有するβ−ラクタマーゼ Download PDF

Info

Publication number
JP6685925B2
JP6685925B2 JP2016562248A JP2016562248A JP6685925B2 JP 6685925 B2 JP6685925 B2 JP 6685925B2 JP 2016562248 A JP2016562248 A JP 2016562248A JP 2016562248 A JP2016562248 A JP 2016562248A JP 6685925 B2 JP6685925 B2 JP 6685925B2
Authority
JP
Japan
Prior art keywords
lactamase
antibiotic
seq
ceftriaxone
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016562248A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017515466A5 (enExample
JP2017515466A (ja
Inventor
カレコ，マイケル
コネリー，シーラ
Original Assignee
シンセティック バイオロジクス，インコーポレイテッド
シンセティック バイオロジクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シンセティック バイオロジクス，インコーポレイテッド, シンセティック バイオロジクス，インコーポレイテッド filed Critical シンセティック バイオロジクス，インコーポレイテッド
Publication of JP2017515466A publication Critical patent/JP2017515466A/ja
Publication of JP2017515466A5 publication Critical patent/JP2017515466A5/ja
Application granted granted Critical
Publication of JP6685925B2 publication Critical patent/JP6685925B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/86—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides, e.g. penicillinase (3.5.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/02—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amides (3.5.2)
    • C12Y305/02006—Beta-lactamase (3.5.2.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2016562248A 2014-04-17 2015-04-17 治療用として改善された特性を有するβ−ラクタマーゼ Expired - Fee Related JP6685925B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461980844P 2014-04-17 2014-04-17
US61/980,844 2014-04-17
US201462046627P 2014-09-05 2014-09-05
US62/046,627 2014-09-05
PCT/US2015/026457 WO2015161243A2 (en) 2014-04-17 2015-04-17 Beta-lactamases with improved properties for therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019220462A Division JP7038094B2 (ja) 2014-04-17 2019-12-05 治療用として改善された特性を有するβ－ラクタマーゼ

Publications (3)

Publication Number Publication Date
JP2017515466A JP2017515466A (ja) 2017-06-15
JP2017515466A5 JP2017515466A5 (enExample) 2018-05-31
JP6685925B2 true JP6685925B2 (ja) 2020-04-22

Family

ID=54321063

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016562248A Expired - Fee Related JP6685925B2 (ja) 2014-04-17 2015-04-17 治療用として改善された特性を有するβ−ラクタマーゼ
JP2019220462A Expired - Fee Related JP7038094B2 (ja) 2014-04-17 2019-12-05 治療用として改善された特性を有するβ－ラクタマーゼ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019220462A Expired - Fee Related JP7038094B2 (ja) 2014-04-17 2019-12-05 治療用として改善された特性を有するβ－ラクタマーゼ

Country Status (10)

Country Link
US (14) US9290754B2 (enExample)
EP (1) EP3132033B1 (enExample)
JP (2) JP6685925B2 (enExample)
KR (1) KR102360582B1 (enExample)
CN (1) CN106163546B (enExample)
AU (1) AU2015247382B2 (enExample)
BR (1) BR112016023360B1 (enExample)
CA (1) CA2942971C (enExample)
RU (1) RU2678124C2 (enExample)
WO (1) WO2015161243A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3204495B1 (en) 2014-10-08 2020-04-22 Synthetic Biologics, Inc. Beta-lactamase formulations and uses thereof
US10709773B2 (en) * 2015-03-06 2020-07-14 Synthetic Biologics, Inc. Safe and effective beta-lactamase dosing for microbiome protection
WO2017144495A1 (en) * 2016-02-23 2017-08-31 Da Volterra Beta-lactamase variants
US10982205B2 (en) 2016-02-23 2021-04-20 Da Volterra Beta-lactamase variants
US11517614B2 (en) 2016-06-28 2022-12-06 Synthetic Biologics, Inc. Microbiome protection from oral antibiotics
EP3829637A1 (en) 2018-08-05 2021-06-09 Da Volterra Method for improving anticancer agent efficacy
CN112689506A (zh) 2018-08-05 2021-04-20 达·沃尔泰拉公司 用于治疗移植物抗宿主疾病的组合物
CN109337889B (zh) * 2018-12-26 2020-10-02 广州白云山拜迪生物医药有限公司 一种酶活提高的金属β-内酰胺酶突变体及其构建方法
CN109576250B (zh) * 2018-12-26 2025-04-15 广州白云山拜迪生物医药有限公司 一种酶活提高的头孢菌素酶突变体及其构建方法
EP3965804B1 (en) * 2019-05-06 2025-04-02 Theriva Biologics, Inc. Beta-lactamase compositions for treatment of graft versus host disease
EP4148136A1 (en) 2021-09-08 2023-03-15 Da Volterra An engineered yeast cell for the delivery of antibiotic-inactivating enzymes
WO2024012487A1 (en) * 2022-07-14 2024-01-18 The Hong Kong Polytechnic University Biosensor comprising a modified beta-lactamase and uses thereof
CN115433701B (zh) * 2022-11-08 2023-03-17 南京农业大学 一株变形杆菌及其菌剂和在降解头孢类抗生素中的应用
CN117701543A (zh) * 2023-12-15 2024-03-15 四川省固体废物与化学品管理中心 一种b家族内酰胺酶突变体及其固定化方法与应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL89987C (enExample) 1954-05-29
US2941995A (en) 1957-08-02 1960-06-21 Beecham Res Lab Recovery of solid 6-aminopenicillanic acid
US2982696A (en) 1959-05-01 1961-05-02 Schenley Ind Inc Ion-exchange procedures for the purification of penicillinase
US3070511A (en) 1960-02-10 1962-12-25 Lepetit Spa Process for preparing 6-aminopenicillanic acid
US3150059A (en) 1962-12-26 1964-09-22 Lilly Co Eli Penicillin deacylation via actinoplanaceae fermentation
US3239394A (en) 1964-06-15 1966-03-08 Merck & Co Inc Process for producing 7-amino-cephalosporanic acid
US3499909A (en) 1966-05-18 1970-03-10 Koninklijke Gist Spiritus Process for production of 6-aminopenicillanic acid
US3488729A (en) 1966-08-22 1970-01-06 Lilly Co Eli Cephalothin ester
GB1241844A (en) 1968-08-23 1971-08-04 Beecham Group Ltd Penicillins
GB1463513A (en) 1974-08-13 1977-02-02 Beecham Group Ltd Enzymes
FI59265C (fi) 1974-08-13 1981-07-10 Beecham Group Ltd Foerfarande foer framstaellning av 6-aminopenicillansyra
GB2199582A (en) 1987-01-07 1988-07-13 Bayer Ag Analogues of pancreatic secretory trypsin inhibitor
FR2613624B1 (fr) 1987-04-10 1990-11-23 Roussy Inst Gustave Composition pharmaceutique, administrable par voie orale, destinee a reduire les effets des b-lactamines
CA2007083A1 (en) 1989-01-09 1990-07-09 Nobuhiko Katunuma Pharmaceutical use of trypstatin
CS275231B2 (en) 1989-09-29 1992-02-19 Ustav Makormolekularni Chemie Medicine bottle
FI920206A0 (fi) 1992-01-17 1992-01-17 Pekka Untamo Heino Medicinsk anvaendning, medicinskt foerfarande och preparat.
EP0837925A1 (en) 1995-07-07 1998-04-29 Novo Nordisk A/S Production of proteins using bacillus incapable of sporulation
CN1363680A (zh) * 2001-01-05 2002-08-14 上海博德基因开发有限公司 一种新的多肽——β内酰胺酶20.24和编码这种多肽的多核苷酸
DK1391502T3 (da) 2001-05-29 2012-05-21 Kao Corp Værtsmikroorganismer
FI112666B (fi) 2001-11-06 2003-12-31 Ipsat Therapies Oy Itiöimätön Bacillus subtilis, sen valmistus ja käyttö
FR2843302B1 (fr) 2002-08-09 2004-10-22 Centre Nat Rech Scient Forme galenique pour la delivrance colique de principes actifs
EP2216640A1 (en) * 2004-01-09 2010-08-11 Novozymes, Inc. Bacillus licheniformis chromosome
EP1564286A1 (en) 2004-02-11 2005-08-17 Université de Liège Hybrid proteins of beta-lactamase class A
DE102004032995A1 (de) * 2004-07-08 2006-03-30 Henkel Kgaa Neue, sekretierte Genprodukte von Bacillus licheniformis und darauf aufbauende verbesserte biotechnologische Produktionsverfahren
JP2008540602A (ja) 2005-05-18 2008-11-20 ダ・ボルテラ 吸着剤の結腸送達
FI119190B (fi) * 2006-06-21 2008-08-29 Ipsat Therapies Oy Modifioitu beta-laktamaasi ja menetelmä sen valmistamiseksi
CN101104858A (zh) * 2006-07-10 2008-01-16 温州医学院 一种体外定向进化获取高活力超广谱β-内酰胺酶的方法
FI119678B (fi) 2006-11-28 2009-02-13 Ipsat Therapies Oy Beta-laktamaasin käyttö
US20100064393A1 (en) * 2006-11-29 2010-03-11 Novozymes, Inc. Bacillus liceniformis chromosome
CN101647022B (zh) * 2007-01-31 2012-07-18 麦科罗医药科技(武汉)有限公司 描述蛋白质的构象和根据折叠、整体形状与结构序列对其进行评价的方法、系统及装置
FI20105572A0 (fi) 2010-05-24 2010-05-24 Prevab R Lcc Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt
US9347057B2 (en) * 2012-06-12 2016-05-24 The Johns Hopkins University Methods for efficient, expansive user-defined DNA mutagenesis

Also Published As

Publication number Publication date
JP7038094B2 (ja) 2022-03-17
US20230313166A1 (en) 2023-10-05
KR102360582B1 (ko) 2022-02-08
US10336995B2 (en) 2019-07-02
RU2678124C2 (ru) 2019-01-23
US11608494B2 (en) 2023-03-21
US20160362674A1 (en) 2016-12-15
EP3132033B1 (en) 2019-10-30
RU2016140627A (ru) 2018-05-17
US20180362954A1 (en) 2018-12-20
US9783797B1 (en) 2017-10-10
US20170314006A1 (en) 2017-11-02
US20180023072A1 (en) 2018-01-25
KR20160144996A (ko) 2016-12-19
CN106163546A (zh) 2016-11-23
EP3132033A2 (en) 2017-02-22
AU2015247382B2 (en) 2020-04-23
JP2017515466A (ja) 2017-06-15
US20150297689A1 (en) 2015-10-22
US20200157521A1 (en) 2020-05-21
CA2942971C (en) 2023-03-14
US9376673B1 (en) 2016-06-28
AU2015247382A1 (en) 2016-09-15
US10767171B2 (en) 2020-09-08
US20160303207A1 (en) 2016-10-20
BR112016023360A2 (enExample) 2017-08-15
RU2016140627A3 (enExample) 2018-11-29
US10584326B2 (en) 2020-03-10
BR112016023360B1 (pt) 2023-03-07
CA2942971A1 (en) 2015-10-22
US11236319B2 (en) 2022-02-01
US9695409B2 (en) 2017-07-04
US9404103B1 (en) 2016-08-02
WO2015161243A2 (en) 2015-10-22
US9464280B1 (en) 2016-10-11
US20180305678A1 (en) 2018-10-25
US20220098566A1 (en) 2022-03-31
US9290754B2 (en) 2016-03-22
EP3132033A4 (en) 2017-11-29
US10087433B1 (en) 2018-10-02
JP2020054368A (ja) 2020-04-09
US20200017844A1 (en) 2020-01-16
US10011824B2 (en) 2018-07-03
US20200347375A1 (en) 2020-11-05
WO2015161243A3 (en) 2016-02-11
CN106163546B (zh) 2021-02-19

Similar Documents

Publication Publication Date Title
JP6685925B2 (ja) 治療用として改善された特性を有するβ−ラクタマーゼ
Yang et al. Biochemical characterization of a beta-lactamase that hydrolyzes penems and carbapenems from two Serratia marcescens isolates
US20120219952A1 (en) Carbapenemase and antibacterial treatment
HK1233513B (en) Beta-lactamases with improved properties for therapy
HK1233513A1 (en) Beta-lactamases with improved properties for therapy
CN106574273B (zh) β-内酰胺酶的基于大肠杆菌的生产
Cheng Structural and functional studies of antibiotic resistance enzymes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180411

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180411

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190605

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191205

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200130

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200303

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200401

R150 Certificate of patent or registration of utility model

Ref document number: 6685925

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees